PUBLISHER: Grand View Research | PRODUCT CODE: 1529717
PUBLISHER: Grand View Research | PRODUCT CODE: 1529717
The U.S. capnography devices market size is expected to reach USD 675.7 million by 2030, registering a CAGR of 7.35% from 2024 to 2030, according to a new report by Grand View Research, Inc. For instance, COPD drives the rising demand for capnography devices due to the need for continuous and accurate respiratory monitoring to manage and detect complications effectively. According to the CDC, in 2021, approximately 14.2 million U.S. adults had physician-diagnosed COPD. Capnography offers real-time assessment of ventilation status, crucial for early detection of respiratory distress and timely intervention in COPD patients. Hence, the need for better patient outcome and enhanced monitoring capabilities are driving the adoption of capnography devices in clinical settings.
Furthermore, COVID-19 contributed to the rising demand for capnography devices in the U.S. by highlighting the critical need for accurate and real-time respiratory monitoring in managing respiratory complications associated with the virus. The pandemic increased hospitalizations and the necessity for effective patient monitoring, especially for those on ventilators or experiencing severe respiratory issues. This surge in demand for enhanced respiratory care and monitoring capabilities significantly boosted the demand for capnography devices benefitting the market players financially. For instance, Masimo increased its product specific segment revenue to USD 1,239.2 million in 2021 from USD 829.9 million in 2018, reflecting a three-year CAGR of 14.3%. This growth is attributed to the expansion of its core SET pulse oximeter customer base, higher revenues from NomoLine capnography and rainbow Pulse CO-Oximetry, and an expanding list of OEM partners.
Furthermore, research indicates that capnography is increasingly important for both intubated and non-intubated patients, as it effectively measures and links to apneic events. Emerging studies are also exploring the combination of etCO2 and rSO2 to enhance the understanding of resuscitation. The technology is expanding, offering opportunities for broader application across the continuum of care, including emergency departments, pre-hospital settings, resuscitation response teams, critical care units, procedural sedation, general care floors, and pain management. Clinicians continue to rely on capnography to gain better insights into individual patient conditions, thereby driving the market in the U.S.
Moreover, market players undertake various growth strategies to grow and sustain in the U.S. capnography devices market. For instance, in June 2023, Royal Philips and Masimo received FDA clearance to activate Regional Oximetry (O3), SedLine Brain Function Monitoring, and CO? measurements in Philips IntelliVue MX850 and MX750 Patient Monitors. This extension of their collaboration allows clinicians to make quick, informed decisions without needing additional monitoring equipment.